Perrigo announces FDA approval, launch for the store brand equivalent of Imodium Multi-Symptom Relief
DUBLIN — Perrigo Company announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer ‘own label’ brands and will provide consumers
